Somaiya Mayur Ian 4

What Happened
Somaiya Mayur Ian, Chief Financial Officer of NewAmsterdam Pharma (NAMS), exercised 100,000 stock options on Jan 20–21, 2026 at $9.26 per share (total cost $926,000) and concurrently sold the 100,000 shares in open-market transactions for aggregate proceeds of approximately $3,260,619. The exercises and immediate sales indicate a cashless exercise pattern: acquired 100,000 shares and disposed of 100,000 shares, leaving no net increase from these transactions.

Key Details

• Transaction dates: exercises on 2026-01-20 (60,216 shares) and 2026-01-21 (39,784 shares); sales on 2026-01-20 and 2026-01-21.
• Exercise price and cost: $9.26 per share; total paid ≈ $926,000.
• Sales proceeds: five grouped sale entries totaling ≈ $3,260,619 (individual sale lots ranged roughly $30.17–$34.31 per share per filing footnotes).
• Net proceeds (proceeds minus exercise cost): ≈ $2,334,619.
• Shares owned after transaction: filing shows no net increase from these transactions (100,000 acquired and 100,000 sold); the report does not state total holdings after the trades.
• Footnotes of note: some sales were effected pursuant to a Rule 10b5‑1 trading plan (footnote F1); multiple sales were executed in several transactions with price ranges noted in footnotes F2–F6; the options were granted Nov 1, 2023 with standard vesting (footnote F7).
• Filing: Reported on 2026-01-22 covering trades on 2026-01-20/21.

Context
For retail investors: exercises followed immediately by market sales are typically cashless exercises used to realize value or cover option costs/taxes and do not by themselves signal management buying the stock. The presence of a 10b5‑1 plan for at least some sales means some trades may have been pre-planned. Purchases generally carry more weight as a bullish signal than routine option exercises and sales.